KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial.

Joanne B Weidhaas, Jonathan Harris, Maura L Gillison, Dukagjin Blakaj, Greg A Krempl, Kristin Higgins, Jack Phan, Neal E Dunlap, Shazia T Mahamood, Jennifer Dorth, Jimmy J Caudell, Anand B Desai, Thomas J Galloway, J Daniel Pennington, Adam Currey, Jennifer Lathrop, Pedro A Torres-Saavedra, D Neil Hayes, Sue S Yom, Quynh-Thu Le

Cancer Res Commun 6(3) 706-713

PMID41790036
PMCIDPMC13036839
DOI10.1158/2767-9764.CRC-25-0551
发表日期2026-03-06
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: NRG/RTOG 1016 was a phase III noninferiority trial comparing IMRT + cisplatin versus IMRT + cetuximab for human papillomavirus-positive oropharyngeal squamous cell cancer (HPV+ OPSCC). A germline mutation (the KRAS-variant) previously identified patients with improved outcomes to radiation + cetuximab + cisplatin; thus, we investigated whether there may be similar benefits for IMRT + cetuximab. PATIENTS AND METHODS: 562 patients were tested, with 16% positive for the KRAS-variant. Clinical endpoints were per NRG/RTOG 1016, and hazard ratios (HR) were estimated by Cox models. Negative binomial regression modeled treatment-related acute and late grade 3 to 5 adverse events (AE). All models included KRAS, assigned treatment, their interaction, and other prognostic variables tested at two-sided 0.05. RESULTS: There was no association between the KRAS-variant and clinical outcomes. There were higher local-regional failure rates (LRF) in nonvariant patients treated with cetuximab [HR = 1.83 (1.19-2.82)] versus KRAS-variant patients [HR (95% CI), 0.90 (0.34-2.41)]. Grade 3 to 4 acute mucositis was higher in nonvariant patients treated with cetuximab [OR = 1.41 (95% CI, 0.98-2.03)] and lower in KRAS-variant patients [OR = 0.60 (95% CI, 0.25-1.41)]. However, the mean late toxicity ratio was lower in nonvariant patients [0.55 (95% CI, 0.35-0.87)] versus KRAS-variant patients [1.62 (95% CI, 0.57-4.62)]. KRAS by treatment interaction for acute and late AEs was not significant (P = 0.0717 and 0.0659, respectively). CONCLUSIONS: Possible lower LRF and less acute toxicity with cetuximab versus cisplatin for KRAS-variant patients seem to be offset by potentially increased late toxicity. Further evaluation of this class of biomarkers is warranted. SIGNIFICANCE: Germline microRNA-disrupting biomarkers are functional biomarkers being studied to help guide treatment personalization in cancer. The work in this study is a hypothesis-generating evaluation of the KRAS-variant as a potential biomarker to help predict outcomes and toxicity in patients with head and neck cancer treated with radiation and cetuximab. Findings from this work suggest that these biomarkers may have the potential to differentiate patients at risk of acute versus late toxicity, supporting further study of these biomarkers in radiation studies.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 1.

LRF by KRAS and assigned treatment. Rates of local failure based on treatment and KRAS- variant status, with KRAS- variant patients being depicted by blue lines and nonvariant patients by red lines and dashed lines representing cetuximab-treated patients.

LRF_by_KRAS_and_assigned_treatment

LRF

Figure 1. · Panel LRF_by_KRAS_and_assigned_treatment

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel LRF_by_KRAS_and_assigned_treatment 是同一 Figure 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2.DM by KRAS and assigned treatment. Distant failure rates based on treatment and KRAS- variant status, with KRAS- variant patients being depicted by blue lines and nonvariant patients by red lines and dashed lines representing cetuximab-treated patients.
非 KM Figure
Figure 3.Grade 3 to 4 treatment-related AEs over time by KRAS and assigned treatment. Rates of treatment-related AEs with 95% CI by treatment and KRAS- variant status, with KRAS- variant patients being depicted by blue (cisplatin-treated) and red (cetuximab-treated) and nonvariant patients depicted by green (cisplatin-treated) and brown (cetuximab-treated).
非 KM Figure